Earnings Per Share
EPS (Diluted)
Regeneron Pharmaceuticals EPS (Diluted) decreased by 13.2% to $6.75 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.2%, from $7.27 to $6.75. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows a downward trend with a -12.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Higher values indicate stronger profitability even when accounting for potential share dilution.
Detailed definition
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Peer comparison
Used by all public companies to provide a realistic view of earnings per share for investors.
Metric ID:
eps_dilutedHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $27.97 | $14.33 | $19.58 | $8.61 | $7.47 | $11.66 | $10.48 | $7.17 | $8.50 | $8.89 | $10.21 | $6.27 | $12.41 | $11.54 | $8.12 | $7.27 | $12.81 | $13.62 | $7.78 | $6.75 |
| QoQ Change | — | -48.8% | +36.6% | -56.0% | -13.2% | +56.1% | -10.1% | -31.6% | +18.5% | +4.6% | +14.8% | -38.6% | +97.9% | -7.0% | -29.6% | -10.5% | +76.2% | +6.3% | -42.9% | -13.2% |
| YoY Change | — | — | — | — | -73.3% | -18.6% | -46.5% | -16.7% | +13.8% | -23.8% | -2.6% | -12.6% | +46.0% | +29.8% | -20.5% | +15.9% | +3.2% | +18.0% | -4.2% | -7.2% |
Range$6.27 – $27.97
CAGR-25.9%
Avg YoY Growth-6.2%
Median YoY Growth-5.7%
Current Streak2 quarters decline
EPS (Diluted) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's eps (diluted)?
- Regeneron Pharmaceuticals (REGN) reported eps (diluted) of $6.75 in Q1 2026.
- How has Regeneron Pharmaceuticals's eps (diluted) changed year-over-year?
- Regeneron Pharmaceuticals's eps (diluted) decreased by 7.2% year-over-year, from $7.27 to $6.75.
- What is the long-term trend for Regeneron Pharmaceuticals's eps (diluted)?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's eps (diluted) has grown at a -12.9% compound annual growth rate (CAGR), from $71.97 to $41.48.
- What does eps (diluted) mean?
- Earnings per share calculated as if all potential shares were issued.